Literature DB >> 34738167

State-of-the-art surgery for Crohn's disease: Part I-small intestine/ileal disease.

Sandra L Kavalukas1,2, Katharina M Scheurlen2, Susan Galandiuk3,4.   

Abstract

The management of Crohn's disease has evolved significantly over the past 20 years. The arrival of biologic therapies has altered not only the management and outcomes but also rates for refractory disease requiring surgery. New surgical techniques have paralleled these medical advances, and this article will provide an overview of these new modalities as well as their outcomes. This is the first of a three-part series and will focus on terminal ileal and ileocolic disease.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Anastomotic leak; Ileal Crohn’s disease; Ileocolic Crohn’s disease; Ileostomy; Kono-S anastomosis; Recurrence; Strictureplasty

Mesh：

Year:  2021        PMID： 34738167     DOI： 10.1007/s00423-021-02324-4

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN： 1435-2443            Impact factor:   3.445


  50 in total

Review 1.  Postoperative recurrent luminal Crohn's disease: a systematic review.

Authors:  Peter De Cruz; Michael A Kamm; Lani Prideaux; Patrick B Allen; Paul V Desmond
Journal:  Inflamm Bowel Dis       Date:  2011-08-09       Impact factor: 5.325

2.  Crohn's disease: influence of age at diagnosis on site and clinical type of disease.

Authors:  J M Polito; B Childs; E D Mellits; A Z Tokayer; M L Harris; T M Bayless
Journal:  Gastroenterology       Date:  1996-09       Impact factor: 22.682

3.  Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.

Authors:  Byong Duk Ye; Marina Pesegova; Olga Alexeeva; Marina Osipenko; Adi Lahat; Andriy Dorofeyev; Sigal Fishman; Olena Levchenko; Jae Hee Cheon; Maria Lia Scribano; Radu-Bogdan Mateescu; Kang-Moon Lee; Chang Soo Eun; Sang Joon Lee; Sung Young Lee; HoUng Kim; Stefan Schreiber; Heather Fowler; Raymond Cheung; Young-Ho Kim
Journal:  Lancet       Date:  2019-03-28       Impact factor: 79.321

4.  Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.

Authors:  Craig Haifer; Ashish Srinivasan; Yoon-Kyo An; Sherman Picardo; Daniel van Langenberg; Shankar Menon; Jakob Begun; Simon Ghaly; Lena Thin
Journal:  Med J Aust       Date:  2020-10-17       Impact factor: 7.738

5.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

6.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

7.  [Crohn's disease: influence of age at diagnosis on clinical type of disease].

Authors:  Héla Elloumi; Souhir Sfar; Ahmed Ben Abdelaziz; Dalenda Arfaoui; Ghouma Mouna; Salem Ajmi
Journal:  Tunis Med       Date:  2007-10

Review 8.  Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.

Authors:  Siew C Ng; Hai Yun Shi; Nima Hamidi; Fox E Underwood; Whitney Tang; Eric I Benchimol; Remo Panaccione; Subrata Ghosh; Justin C Y Wu; Francis K L Chan; Joseph J Y Sung; Gilaad G Kaplan
Journal:  Lancet       Date:  2017-10-16       Impact factor: 79.321

9.  Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.

Authors:  Martin Lukas; K Malickova; M Kolar; M Bortlik; M Vasatko; N Machkova; V Hruba; D Duricova; Milan Lukas
Journal:  J Crohns Colitis       Date:  2020-07-30       Impact factor: 9.071

10.  Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study.

Authors:  Davide Giuseppe Ribaldone; Gian Paolo Caviglia; Rinaldo Pellicano; Marta Vernero; Giorgio Maria Saracco; Mario Morino; Marco Astegiano
Journal:  Rev Esp Enferm Dig       Date:  2020-03       Impact factor: 2.086
View more
  2 in total

Review 1.  State-of-the-art surgery for Crohn's disease: Part II-colonic Crohn's disease and associated neoplasms.

Authors:  Anne Macleod; Sandra L Kavalukas; Katharina M Scheurlen; Susan Galandiuk
Journal:  Langenbecks Arch Surg       Date:  2022-06-22       Impact factor: 3.445

Review 2.  Intestinal strictures in Crohn's disease: a 2021 update.

Authors:  Xiaoxuan Lin; Yu Wang; Zishan Liu; Sinan Lin; Jinyu Tan; Jinshen He; Fan Hu; Xiaomin Wu; Subrata Ghosh; Minhu Chen; Fen Liu; Ren Mao
Journal:  Therap Adv Gastroenterol       Date:  2022-06-21       Impact factor: 4.802
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.